A low level of high-density lipoprotein cholesterol (HDL-C) is one of the common types of dyslipidemia in patients with early coronary artery diseases (CADs) and has a strong, inverse, and independent association with the incidence of these disorders (
1,
2). Therefore, any reduction in HDL increases the risk of CADs by 2% - 3% (
3). The frequency of low HDL levels, either alone or combined with other lipid disorders, varies across countries (6% to 34%) (
4). According to the report of the National Center for Health Statistics, the prevalence of low HDL levels in adults was 21.3% in 2009 - 2010 (
5) and 19% in 2011 - 2014 (
1). Low HDL is more common in Asian populations. A systematic review of 37 studies in Asia revealed that 33.1% of the population had low HDL levels (
4). According to several studies on the prevalence of dyslipidemia in Iran, 43.9% of the studied population had low HDL levels (
6). In another study in Iran, 13% of women and 30% of men in Tehran had HDL levels lower than 35 mg/dL (
7). In addition, in northwestern Iran, 73% of the people aged 20 years and above had HDL abnormalities (
8). In a study on adolescents in Birjand, 24.7% had HDL levels lower than 40 mg/dL (
9).
The molecular mechanisms of the biological effects of HDL on CADs remain unknown. Various roles of HDL, as a protective factor against CADs, include enhancing macrophage cholesterol efflux and reversing cholesterol transport, as well as its anti-inflammatory, anti-thrombolytic, anti-apoptotic, and antioxidant properties (
10).
Coronary artery diseases are associated not only with dyslipidemia and metabolic syndrome, including hypertension and diabetes mellitus, but also with unhealthy behaviors such as smoking, physical inactivity, and an unhealthy diet (
11). These vascular risk factors are generally controlled using a combination of drugs and lifestyle modifying measures, including quitting smoking, choosing healthy foods, increasing physical activity, and using adequate medications for a lifetime (
12,
13).